Published in Stem Cell Res Ther on November 16, 2011
Transgene-free disease-specific induced pluripotent stem cells from patients with type 1 and type 2 diabetes. Stem Cells Transl Med (2012) 1.02
Derivation of autism spectrum disorder-specific induced pluripotent stem cells from peripheral blood mononuclear cells. Neurosci Lett (2012) 0.89
Concise review: pluripotent stem cell-based regenerative applications for failing β-cell function. Stem Cells Transl Med (2014) 0.88
The multi-differentiation potential of peripheral blood mononuclear cells. Stem Cell Res Ther (2012) 0.85
Generation of human iPSCs from cells of fibroblastic and epithelial origin by means of the oriP/EBNA-1 episomal reprogramming system. Stem Cell Res Ther (2015) 0.84
The 3R principle: advancing clinical application of human pluripotent stem cells. Stem Cell Res Ther (2013) 0.79
Induced pluripotent stem cells in hematology: current and future applications. Blood Cancer J (2014) 0.76
Tumor-Free Transplantation of Patient-Derived Induced Pluripotent Stem Cell Progeny for Customized Islet Regeneration. Stem Cells Transl Med (2016) 0.76
Recent developments in ex vivo platelet production. Cytotechnology (2016) 0.75
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 120.51
Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell (2007) 101.42
Induced pluripotent stem cell lines derived from human somatic cells. Science (2007) 71.50
Generation of germline-competent induced pluripotent stem cells. Nature (2007) 32.77
Reprogramming of human somatic cells to pluripotency with defined factors. Nature (2007) 30.84
In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature (2007) 28.24
Human induced pluripotent stem cells free of vector and transgene sequences. Science (2009) 17.16
Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci U S A (2008) 13.09
piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature (2009) 11.27
Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell (2008) 10.68
Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol (2008) 10.63
Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science (2008) 10.55
Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature (2009) 9.29
Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency. Cell Stem Cell (2011) 6.11
Generation of induced pluripotent stem cells from human blood. Blood (2009) 4.92
No-nonsense functions for long noncoding RNAs. Cell (2011) 4.23
Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood (2009) 4.22
Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. Nat Biotechnol (2011) 4.06
Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell (2010) 4.03
Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Res (2011) 3.58
Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci U S A (2009) 3.43
Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. Cell Stem Cell (2009) 3.12
Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell (2010) 3.08
Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation (2009) 2.93
Reprogramming of T cells from human peripheral blood. Cell Stem Cell (2010) 2.93
Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell (2009) 2.78
Generation of insulin-secreting islet-like clusters from human skin fibroblasts. J Biol Chem (2008) 2.04
Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood (2011) 1.92
Reprogrammed mouse fibroblasts differentiate into cells of the cardiovascular and hematopoietic lineages. Stem Cells (2008) 1.83
iPS programmed without c-MYC yield proficient cardiogenesis for functional heart chimerism. Circ Res (2009) 1.77
Isolation and cultivation of human keratinocytes from skin or plucked hair for the generation of induced pluripotent stem cells. Nat Protoc (2010) 1.67
Postentry restriction to human immunodeficiency virus-based vector transduction in human monocytes. J Virol (2001) 1.60
Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes. PLoS One (2010) 1.54
Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells. Blood (2009) 1.49
Reprogramming of EBV-immortalized B-lymphocyte cell lines into induced pluripotent stem cells. Blood (2011) 1.34
Indolactam V/GLP-1-mediated differentiation of human iPS cells into glucose-responsive insulin-secreting progeny. Gene Ther (2010) 1.21
Induced pluripotent reprogramming from promiscuous human stemness related factors. Clin Transl Sci (2009) 1.20
Effective generation of iPS cells from CD34+ cord blood cells by inhibition of p53. Exp Hematol (2009) 1.16
Cyclosporine increases human immunodeficiency virus type 1 vector transduction of primary mouse cells. J Virol (2006) 1.09
Human lymphoblastoid B-cell lines reprogrammed to EBV-free induced pluripotent stem cells. Blood (2011) 1.08
Direct generation of induced pluripotent stem cells from human nonmobilized blood. Stem Cells Dev (2010) 1.06
Successful differentiation to T cells, but unsuccessful B-cell generation, from B-cell-derived induced pluripotent stem cells. Int Immunol (2010) 0.96
Reprogrammed keratinocytes from elderly type 2 diabetes patients suppress senescence genes to acquire induced pluripotency. Aging (Albany NY) (2012) 0.96
Embryonic stem cells: are useful in clinic treatments? J Physiol Biochem (2011) 0.80
Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. Cell Metab (2011) 4.15
Fibulin-5/DANCE is essential for elastogenesis in vivo. Nature (2002) 3.60
Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med (2005) 3.59
Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care (2012) 3.20
Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation (2009) 2.93
Telecare for patients with type 1 diabetes and inadequate glycemic control: a randomized controlled trial and meta-analysis. Diabetes Care (2004) 2.93
Defective regulation of interdomain interactions within the ryanodine receptor plays a key role in the pathogenesis of heart failure. Circulation (2005) 2.42
Posttransplantation diabetes: a systematic review of the literature. Diabetes Care (2002) 2.39
Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood (2010) 2.38
Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med (2002) 2.37
Rhesus monkey TRIM5alpha restricts HIV-1 production through rapid degradation of viral Gag polyproteins. Nat Med (2007) 2.32
Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate (2010) 2.22
Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury. Am J Physiol Heart Circ Physiol (2006) 2.01
Use of CD134 as a primary receptor by the feline immunodeficiency virus. Science (2004) 1.93
Dystrophic calcification as a cause for non healing leg ulcers. Int Wound J (2005) 1.82
Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol (2009) 1.80
Pro-B-type natriuretic peptide(1-108) circulates in the general community: plasma determinants and detection of left ventricular dysfunction. J Am Coll Cardiol (2011) 1.78
iPS programmed without c-MYC yield proficient cardiogenesis for functional heart chimerism. Circ Res (2009) 1.77
Altered intracellular Ca2+ handling in heart failure. J Clin Invest (2005) 1.70
Moyamoya disease in a primarily white, midwestern US population: increased prevalence of autoimmune disease. Stroke (2013) 1.68
Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor. Circ Res (2010) 1.61
Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. J Am Coll Cardiol (2012) 1.61
Evaluation of Gen-Probe amplified mycobacterium tuberculosis direct test by using respiratory and nonrespiratory specimens in a tertiary care center laboratory. J Clin Microbiol (2002) 1.56
Renal vein cytokine release as an index of renal parenchymal inflammation in chronic experimental renal artery stenosis. Nephrol Dial Transplant (2013) 1.56
Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol (2010) 1.53
Diurnal pattern of insulin action in type 1 diabetes: implications for a closed-loop system. Diabetes (2013) 1.51
The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res (2006) 1.50
Tongue muscle-derived stem cells express connexin 43 and improve cardiac remodeling and survival after myocardial infarction in mice. Circ J (2010) 1.50
Identification and physiological activity of survival factor released from cardiomyocytes during ischaemia and reperfusion. Cardiovasc Res (2008) 1.49
Alpha interferon enhances TRIM5alpha-mediated antiviral activities in human and rhesus monkey cells. J Virol (2007) 1.49
Lentiviral vectors: basic to translational. Biochem J (2012) 1.49
Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res (2009) 1.48
Diurnal pattern to insulin secretion and insulin action in healthy individuals. Diabetes (2012) 1.46
Mechanisms of Disease: ryanodine receptor defects in heart failure and fatal arrhythmia. Nat Clin Pract Cardiovasc Med (2006) 1.41
Clinical review: Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab (2008) 1.39
Receptor interacting protein kinase mediates necrotic cone but not rod cell death in a mouse model of inherited degeneration. Proc Natl Acad Sci U S A (2012) 1.37
The mechanism of Axl-mediated Ebola virus infection. J Infect Dis (2007) 1.36
Platelet lysate consisting of a natural repair proteome supports human mesenchymal stem cell proliferation and chromosomal stability. Cell Transplant (2010) 1.34
Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest (2004) 1.33
Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation (2011) 1.33
Time lag of glucose from intravascular to interstitial compartment in humans. Diabetes (2013) 1.32
Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene. Mol Ther (2005) 1.30
Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood (2009) 1.28
Defective domain-domain interactions within the ryanodine receptor as a critical cause of diastolic Ca2+ leak in failing hearts. Cardiovasc Res (2008) 1.27
Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J Immunol (2004) 1.26
Early diagnosis is vital in the management of squamous cell carcinomas associated with chronic non healing ulcers: a case series and review of the literature. Int Wound J (2004) 1.25
Scavenging free radicals by low-dose carvedilol prevents redox-dependent Ca2+ leak via stabilization of ryanodine receptor in heart failure. J Am Coll Cardiol (2007) 1.24
Laboratory evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology (2012) 1.24
Correction of defective interdomain interaction within ryanodine receptor by antioxidant is a new therapeutic strategy against heart failure. Circulation (2005) 1.23
No association of xenotropic murine leukemia virus-related virus with prostate cancer or chronic fatigue syndrome in Japan. Retrovirology (2011) 1.22
Association of an increased frequency of CD14+ HLA-DR lo/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). Br J Haematol (2011) 1.21
Obesity in living kidney donors: clinical characteristics and outcomes in the era of laparoscopic donor nephrectomy. Am J Transplant (2005) 1.20
Induced pluripotent reprogramming from promiscuous human stemness related factors. Clin Transl Sci (2009) 1.20
Ischemic pre-conditioning enhances the mobilization and recruitment of bone marrow stem cells to protect against ischemia/reperfusion injury in the late phase. J Am Coll Cardiol (2009) 1.20
Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology (2012) 1.20
Inhibition of nuclear translocation of apoptosis-inducing factor is an essential mechanism of the neuroprotective activity of pigment epithelium-derived factor in a rat model of retinal degeneration. Am J Pathol (2008) 1.20
Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res (2012) 1.19
Intrapatient variations in type 1 diabetes-specific iPS cell differentiation into insulin-producing cells. Mol Ther (2012) 1.19
Xenotropic murine leukemia virus-related virus is susceptible to AZT. Virology (2009) 1.19
No evidence of XMRV in prostate cancer cohorts in the Midwestern United States. Retrovirology (2011) 1.18
Can serum beta-hydroxybutyrate be used to diagnose diabetic ketoacidosis? Diabetes Care (2008) 1.17
Perinatal loss of Nkx2-5 results in rapid conduction and contraction defects. Circ Res (2008) 1.16
Defective calmodulin binding to the cardiac ryanodine receptor plays a key role in CPVT-associated channel dysfunction. Biochem Biophys Res Commun (2010) 1.16
Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med (2013) 1.16
Novel targets for HIV therapy. Antiviral Res (2008) 1.15
Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum (2007) 1.14
Early events in retrovirus XMRV infection of the wild-derived mouse Mus pahari. J Virol (2010) 1.13
Successful disease-specific induced pluripotent stem cell generation from patients with kidney transplantation. Stem Cell Res Ther (2011) 1.12
Cyclosporine increases human immunodeficiency virus type 1 vector transduction of primary mouse cells. J Virol (2006) 1.09
Human immunodeficiency virus type 1 vectors with alphavirus envelope glycoproteins produced from stable packaging cells. J Virol (2005) 1.09
Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clin Cancer Res (2010) 1.08
Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. Am J Hematol (2009) 1.08
Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy. FASEB J (2006) 1.08
c-MYC independent nuclear reprogramming favors cardiogenic potential of induced pluripotent stem cells. J Cardiovasc Transl Res (2010) 1.08
Induced pluripotent stem cell intervention rescues ventricular wall motion disparity, achieving biological cardiac resynchronization post-infarction. J Physiol (2013) 1.08
The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells. Mol Ther (2007) 1.07
Quantitative estimation of insulin sensitivity in type 1 diabetic subjects wearing a sensor-augmented insulin pump. Diabetes Care (2013) 1.07
Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses. J Virol (2007) 1.06
Insulin sensitizers. Mayo Clin Proc (2003) 1.05
Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase in mice. Ann N Y Acad Sci (2006) 1.05
Long-term benefits of pancreas transplantation. Curr Opin Organ Transplant (2008) 1.05
Lentiviral vector-mediated SERCA2 gene transfer protects against heart failure and left ventricular remodeling after myocardial infarction in rats. Mol Ther (2008) 1.05
High-resolution molecular validation of self-renewal and spontaneous differentiation in clinical-grade adipose-tissue derived human mesenchymal stem cells. J Cell Biochem (2014) 1.03
Critical involvement of extracellular ATP acting on P2RX7 purinergic receptors in photoreceptor cell death. Am J Pathol (2011) 1.02
Transgene-free disease-specific induced pluripotent stem cells from patients with type 1 and type 2 diabetes. Stem Cells Transl Med (2012) 1.02
Dendritic cell microvilli: a novel membrane structure associated with the multifocal synapse and T-cell clustering. Blood (2008) 1.01
Low incidence of spontaneous type 1 diabetes in non-obese diabetic mice raised on gluten-free diets is associated with changes in the intestinal microbiome. PLoS One (2013) 1.00
Hepatocyte-like cells differentiated from human induced pluripotent stem cells: relevance to cellular therapies. Stem Cell Res (2012) 1.00
Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. Br J Haematol (2009) 1.00
Epidemiology of infections requiring hospitalization during long-term follow-up of pancreas transplantation. Transplantation (2010) 0.99
Immunotherapeutic agents in type 1 diabetes: a systematic review and meta-analysis of randomized trials. Clin Endocrinol (Oxf) (2008) 0.99